Scientific Advisory Board

Infectious Disease Experts

J. Carl Craft, M.D.

Infectious Disease Chair

Dr. J. Carl Craft was the Chief Executive Officer and Chief Medical Officer of Aquarius Biotechnologies from 2012 until its merger with Matinas BioPharma in 2015. From 2002 to 2007, he was Chief Scientific Officer for Medicines for Malaria Venture (MMV) in Geneva, which had the largest ever anti-malarial drug development portfolio, with 20 programs, of which three were in Phase 3 clinical trials. Prior to this, Dr. Craft worked at Abbott Laboratories as the "Venture Head" of the Anti-Infective Development Group for more than 15 years. Earlier in his career, he was at Tulane University in the Department of Pediatrics Infectious Diseases and Department of Pathology, where he was the Director of Pediatric Closed at the Care Charity Hospital of New Orleans and Director of The Clinical Microbiology Laboratory Tulane Medical Center. He served for two years in the Navy with a rank of Lieutenant Commander and was Chief of Pediatrics at the U.S. Naval Regional Medical Center, Guam, M.I. Dr. Craft serves on the Scientific Advisory Boards for CEMPRA, Drugs for Neglected Disease Institute (DNDi), and ANACOR BMG. He was a Research Fellow in Pediatric Infectious Diseases at The University of Texas, Southwestern Medical School under Drs. John Nelson and George McCracken. He did his residency in Pediatrics at Milwaukee Children's Hospital. He received his M.D. from The George Washington University, Medical School.

Prof. Oliver Cornely, M.D., FACP, FIDSA

Dr. Cornely is Professor of Internal Medicine and Attending Physician at the 1st Department of Internal Medicine, and Medical Director of the Center of Clinical Trials (ZKS) at the Medical Faculty, both located at the Uniklinik Köln, Cologne, Germany.  Dr. Cornely received his medical degree from the University Hospital at Albertus Magnus University, Cologne, in 1994, where he also completed his residency. He then became an intern at the St. Katharinen Hospital, Frechen, Germany. He passed the Board Examinations in internal medicine, infectious diseases, haematology/oncology, and emergency medicine.  Originating from an HIV/AIDS clinical research group, Dr. Cornely’s research interests include invasive fungal diseases in haematology/oncology and in the ICU setting. Dr Cornely is also a clinical infectious diseases consultant at the University Hospital of Cologne. Dr Cornely was recently elected President of the European Confederation of Medical Mycology for a 3-year term. He is past-President of the German-speaking Mycological Society, reviewer for numerous international journals, editorial board member for international journals such as Haematologica, Infectious Disease and Clinical Investigation, Editor in Chief of Mycoses, and a sought after invited speaker at numerous international and national conferences and popular workshop leader.

Dimitrios P. Kontoyiannis, M.D., M.S., Sc.D., PhD (Hon),FACP, FIDSA, FECMM

Dr Dimitrios P. Kontoyiannis received his medical degree Summa Cum Laude from the National and Kapodistrian University of Athens in Greece. He then did a post-doctoral clinical research fellowship in Mycology at the Section of Infectious Diseases at The University of Texas MD Anderson Cancer Center in Houston, TX, followed by training in Internal Medicine at Baylor College of Medicine in Houston, TX, where he served as a Chief Medical Resident. He was subsequently trained as a clinical fellow in Infectious Diseases at Massachusetts General Hospital and obtained a Master in Clinical Sciences from Harvard Medical School in Boston. He spent 3 years at the Whitehead Institute for Biomedical Sciences/Massachusetts Institute of Technology as a fellow in the Harvard MIT Clinical Investigators Training Program. He is currently the Director of the Mycology Research Program and Professor in the Department of Infectious Diseases Infection Control and Employee Health at The University of Texas MD Anderson Cancer Center. He is also an adjunct professor at the University of Houston College of Pharmacy. He serves as an associate editor for Medical Mycology and sits in the editorial Boards of Antimicrobial Agents & Chemotherapy, Medical Mycology and Transplantation Infectious Diseases and he is a reviewer in several peer-reviewed journals in Infectious Diseases, Oncology and Hematology. He has authored more than 170 peer-reviewed manuscripts and over 30 invited articles and book chapters.

Peter G. Pappas, M.D., FACP

Dr. Pappas is the William E. Dismukes Professor of Medicine in the Division of Infectious Diseases in the Department of Medicine at the University of Alabama at Birmingham, and the Principal Investigator for the Mycoses Study Group Education and Research Consortium (MSGERC) which performs multicenter trials, creates treatment guidelines for invasive mycoses, and coordinates training in the epidemiology, diagnosis and treatment of invasive mycoses. He is an internationally recognized expert in the treatment and diagnosis of invasive fungal infections with expertise in the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses, and cryptococcosis. Over the last 25 years, Dr. Pappas has led numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis, and histoplasmosis through his involvement with the National Institute of Allergy and Infectious Disease (NIAID) Bacteriology and Mycology Study Group (BAMSG) and the MSGERC. Dr. Pappas was the principal investigator of a national network of transplant centers, TRANSNET, a collaborative effort of the Centers for Disease Control and Prevention (CDC) and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. He is also the co-principal investigator of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by the CDC. Dr. Pappas joined the faculty at the University of Alabama in Birmingham School of Medicine in 1988, with a focus on HIV and transplant-associated opportunistic infections, especially the invasive mycoses. Previously, he was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, North Carolina. Dr. Pappas earned his medical degree in 1978 from the University of Alabama School of Medicine in Birmingham. He completed his residency in internal medicine, chief medical residency, and infectious diseases fellowship at the University of Washington in Seattle.

David S. Perlin, Ph.D.

Dr. Perlin is Executive Director of the Public Health Research Institute (PHRI) and the Rutgers Regional Biocontainment Laboratory (RBL) of New Jersey Medical School (NJMS), Rutgers Biomedical and Health Sciences. He is also a Professor of Microbiology, Biochemistry and Molecular Genetics at NJMS. Dr. Perlin is an internationally recognized expert and research scientist in infectious diseases who has played a major role in advancing the national research agenda in biodefense and emerging infectious diseases. His primary expertise is in fungal infections, mechanisms of antifungal drug resistance, and rapid diagnosis of opportunistic drug resistant bacterial and fungal pathogens in high-risk patients. Dr. Perlin is the editor-in-chief of the new open access "Journal of Fungi." He serves on the Board of Directors of the Aaron Diamond AIDS Research Center, and on advisory boards and committees for the Clinical and Laboratory Standards Institute (CLSI), Leading International Fungal Education (LIFE), various pharmaceutical and biotech companies, PinnacleCare and the American Society for Microbiology (ASM). Dr. Perlin also serves on advisory and planning boards for several major international conferences, and he is a member of the Steering Committee for Microbiology, Immunology & Infectious Diseases of the New York Academy of Sciences. He earned a Ph.D. from Cornell University and pursued postdoctoral studies at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry. Dr. Perlin was named a Fellow of the New York Academy of Sciences in 2005, and a Visiting Professor at the University of Manchester, UK in 2009.